Syntax Research, Inc. Viking Therapeutics, Inc. Transaction History
Syntax Research, Inc.
- $145 Billion
- Q1 2025
A detailed history of Syntax Research, Inc. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Syntax Research, Inc. holds 200 shares of VKTX stock, worth $5,546. This represents 0.0% of its overall portfolio holdings.
Number of Shares
200
Previous 200
-0.0%
Holding current value
$5,546
Previous $8.05 Million
39.99%
% of portfolio
0.0%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding VKTX
# of Institutions
434Shares Held
65.3MCall Options Held
8.28MPut Options Held
3.39M-
Vanguard Group Inc Valley Forge, PA10.2MShares$282 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$167 Million0.01% of portfolio
-
State Street Corp Boston, MA4.06MShares$112 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY3.13MShares$86.7 Million0.01% of portfolio
-
Morgan Stanley New York, NY3.12MShares$86.5 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.13B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...